Results 1 to 10 of about 1,278,456 (199)

Vogt–Koyanagi–Harada Syndrome (VKHS): First Two Cases Reported in Pediatric Age Group in Oman [PDF]

open access: yesCase Reports in Pediatrics, 2023
The Vogt–Koyanagi–Harada syndrome (VKHS) is a unique form of granulomatous autoimmune disease that mostly impacts the pigmented tissues of the body. The main feature is bilateral granulomatous panuveitis, which is detected on ophthalmologic examination ...
Samiya Al Hashmi   +2 more
doaj   +4 more sources

Vogt-Koyanagi-Harada Syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine [PDF]

open access: yesInternational Journal of Retina and Vitreous, 2021
The challenge of COVID-19 has rapidly changed medical management worldwide. The relatively small time from pandemic to vaccines regulatory approval triggered a race toward vaccines development.
Janaína Jamile Ferreira Saraceno   +4 more
doaj   +3 more sources

Vogt-koyanagi-harada syndrome - A neurologist's perspective [PDF]

open access: yesAnnals of Indian Academy of Neurology, 2021
Vogt-Koyanagi-Harada (VKH) syndrome is an immune-mediated granulomatous disease which affects melanin-rich organs like eyes, skin, nervous system, and ears. Neurological and auditory manifestations usually precede the involvement of other sites. Patients
Sumanth Shivaram   +12 more
doaj   +3 more sources

Adalimumab Reprograms M1 Macrophages to Attenuate Th1/Th17 Responses in Behçet's Uveitis and Vogt-Koyanagi-Harada Syndrome. [PDF]

open access: yesInvest Ophthalmol Vis Sci
Purpose To investigate the effects and underlying mechanisms of adalimumab on monocyte-derived macrophage polarization and CD4+ T cell responses in patients with Behçet's uveitis (BU) or Vogt–Koyanagi–Harada (VKH) syndrome.
Zhu Y   +12 more
europepmc   +2 more sources

Uveitis including Vogt-Koyanagi-Harada syndrome following inactive covid-19 vaccination: a case series. [PDF]

open access: yesJ Ophthalmic Inflamm Infect, 2023
Background Currently, large populations have been vaccinated against COVID-19. The whole inactivated Sinopharm COVID-19 vaccine has been the main available COVID-19 vaccine in Iran.
Shariati MM   +5 more
europepmc   +2 more sources

Common practice patterns in the diagnosis and management of Vogt-Koyanagi-Harada syndrome: a survey study of uveitis specialists. [PDF]

open access: yesFront Ophthalmol (Lausanne), 2023
Introduction Vogt–Koyanagi–Harada (VKH) syndrome is an inflammatory condition characterized by bilateral, granulomatous panuveitis with or without systemic manifestations, and accounts for up to 18% of referrals for panuveitis at tertiary centers in the ...
Choo CH, Acharya NR, Shantha JG.
europepmc   +2 more sources

Vogt-Koyanagi-Harada syndrome in the setting of COVID-19 infection. [PDF]

open access: yesClin Case Rep, 2023
To report a case of Vogt–Koyanagi–Harada disease (VKH) in a 27‐year‐old male 2 weeks proceeding COVID‐19 infection onset. Severe complications of VKH can be avoided by early diagnosis and adequate treatment with corticosteroids and immunosuppressants. It
Eatz T, Charles JH.
europepmc   +2 more sources

A case presentation of an IgA nephropathy patient with Vogt-Koyanagi-Harada syndrome [PDF]

open access: yesBMC Nephrology, 2020
Background Vogt-Koyanagi-Harada syndrome is a rare disease characterized by skin and eyelash bleaching, chronic granulomatous iridocyclitis and exudative retinal detachment, and aseptic meningitis and encephalopathy.
Quan Zhang   +3 more
doaj   +2 more sources

Comprehensive Proteomic Profiling of Aqueous Humor in Idiopathic Uveitis and Vogt-Koyanagi-Harada Syndrome. [PDF]

open access: yesACS Omega
Idiopathic uveitis (IU) and Vogt–Koyanagi–Harada (VKH) syndrome are common types of uveitis. However, the exact pathological mechanisms of IU and VKH remain unclear.
Wu L   +7 more
europepmc   +2 more sources

Premature Ovarian Insufficiency in a Patient With Vogt-Koyanagi-Harada Syndrome: An Unusual Association-A Case Report. [PDF]

open access: yesCase Rep Med
Premature ovarian insufficiency (POI) is a clinical syndrome characterized by ovarian failure in women of reproductive age before the age of 40 years. Its main manifestations include menstrual cycle disturbances, such as oligomenorrhea or amenorrhea. The etiology of POI is highly heterogeneous, with a particular emphasis on genetic and immunological ...
Rocha RB   +7 more
europepmc   +2 more sources

Home - About - Disclaimer - Privacy